Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I multiple-dose study of CSPCHA115 in healthy Chinese volunteers
NCT04161547Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CSPCHA115 in asthma and allergic rhinitis (AR) (4 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Number and incidence of subjects with Adverse Events at 12 days, Number of subjects with clinically significant symptoms abnormalities at 10 days and 17 more. Started Dec 2019; status: completed.
02
Drugs
CSPCHA115
03
Conditions
asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04161547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161547.